Estimates of costs for modelling return on investment from smoking cessation interventions by Trapero Bertran, M et al.
Estimates of costs for modelling return on investment
from smoking cessation interventions
Marta Trapero-Bertran1,2, Reiner Leidl3,4, Celia Muñoz1, Puttarin Kulchaitanaroaj5,
Kathryn Coyle5,6, Maximilian Präger3, Judit Józwiak-Hagymásy7, Kei Long Cheung8,
Mickael Hiligsmann8, Subhash Pokhrel5 & on behalf of the EQUIPT Study Group
Centre of Research in Economics and Health (CRES-UPF) University Pompeu Fabra, Barcelona, Spain,1 Faculty of Economics and Social Sciences, Universitat Internacional
de Catalunya (UIC), Barcelona, Spain,2 Institute of Health Economics and Health Care Management, Helmholtz Zentrum München (GmbH) - German Research Center
for Environmental Health, Comprehensive Pneumology Center Munich (CPC-M), Member of the German Center for Lung Research (DZL), Neuherberg, Germany,3
Munich Center of Health Sciences, Ludwig-Maximilians-University, Munich, Germany,4 Health Economics Research Group, Institute of Environment, Health and
Societies, Brunel University London, Uxbridge, UK,5 Department of Epidemiology and Community Medicine, Faculty of Medicine, University of Ottawa, Ottawa,
Canada,6 Faculty of Social Sciences, Department of Health Policy and Health Economics, Eötvös Loránd University, and Syreon Research Institute, Budapest, Hungary7
and CAPHRI Care and Public Health Research Institute, Department of Health Services Research, Maastricht University, Maastricht, the Netherlands8
ABSTRACT
Background and aims Modelling return on investment (ROI) from smoking cessation interventions requires estimates
of their costs and benefits. This paper describes a standardized method developed to source both economic costs of tobacco
smoking and costs of implementing cessation interventions for a Europe-wide ROI model [European study on Quantifying
Utility of Investment in Protection from Tobacco model (EQUIPTMOD)]. Design Focused search of administrative and
published data. A standardized checklist was developed in order to ensure consistency in methods of data collection.
Setting and participants Adult population (15+ years) in Hungary, Netherlands, Germany, Spain and England. For
passive smoking-related costs, child population (0–15 years) was also included. Measurements Costs of treating
smoking-attributable diseases; productivity losses due to smoking-attributable absenteeism; and costs of implementing
smoking cessation interventions. Findings Annual costs (per case) of treating smoking attributable lung cancer were
between €5074 (Hungary) and €52106 (Germany); coronary heart disease between €1521 (Spain) and €3955
(Netherlands); chronic obstructive pulmonary disease between €1280 (England) and €4199 (Spain); stroke between
€1829 (Hungary) and €14880 (Netherlands). Costs (per recipient) of smoking cessation medications were estimated to
be: for standard duration of varenicline between €225 (England) and €465 (Hungary); for bupropion between €25
(Hungary) and €220 (Germany). Costs (per recipient) of providing behavioural support were also wide-ranging: one-to-
one behavioural support between €34 (Hungary) and €474 (Netherlands); and group-based behavioural support between
€12 (Hungary) and €257 (Germany). The costs (per recipient) of delivering brief physician advice were: €24 (England); €9
(Germany); €4 (Hungary); €33 (Netherlands); and €27 (Spain). Conclusions Costs of treating smoking-attributable
diseases as well as the costs of implementing smoking cessation interventions vary substantially across Hungary,
Netherlands, Germany, Spain and England. Estimates for the costs of these diseases and interventions can contribute to
return on investment estimates in support of national or regional policy decisions.
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INTRODUCTION
Tobacco smoking imposes economic costs on society, as
more resources need to be committed to treating
smoking-attributable diseases [1]. In addition, smoking
causes people to lose time from their regular activities
and results in premature deaths [2]. Determining the
economic burden of smoking, both in terms of direct
health-care costs and the value of lost time and prema-
ture deaths, can help to make the case for investment.
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However, further modelling would be required to show
how to invest. In model-based economic evaluations,
the life-time benefits of tobacco cessation interventions
are compared against the total costs (in this case the
economic burden/costs plus the cost of implementing
services) to show which intervention(s) provide good
value for money [3].
Modelling the return on investment (ROI) from
tobacco cessation interventions therefore requires esti-
mates of their costs and benefits. The economic costs
of smoking have been estimated in several countries
[4–6]. Similarly, costs of implementing tobacco cessation
services are also available for different countries [7–9].
These costs are often estimates based on the availability
of data and resources at the time such studies are con-
ducted, and therefore are likely to vary across studies
and between contexts [3]. For a ROI model that works
for several countries, a standardized method to source
and/or estimate costs (both economic costs of tobacco
and costs of implementing interventions) is required. In
this paper, we describe the standardized methods used
to develop a Europe-wide ROI model for tobacco control
[European study on Quantifying Utility of Investment in
Protection from Tobacco model (EQUIPTMOD)] and
present summary findings [10]. The countries included
in this study were: England, Germany, Hungary,
Netherlands and Spain.
METHODS
Development of standardized framework
The EQUIPTMOD requires both local population and
smoking prevalence data in combination with
intervention-related input estimates (i.e. effectiveness,
reach and costs) [10]. The National Institute for Health
and Care Excellence (NICE) tobacco ROI tool, developed
by NICE in the United Kingdom, served as a starting-
point to identify different types of costs [11]. To obtain
the best available cost estimates, a focused search of
administrative and published data was carried out.
The available data and their sources were subject
to a standardized checklist (Supporting information,
Appendix S1) to ensure that all relevant attributes were
captured uniformly across the countries in evaluating
their relevance to the ROI modelling. Data collection
took place in 2014/15 in the five countries. The stan-
dardized checklist also ensured that countries reported
technical details and sources of the data explicitly and
in a transparent manner, including any deviation from
the agreed core framework used for data collection.
The checklist was informed by best reporting guidelines
advocated by major journals for reporting economic
evaluation studies [12–14].
Identification of cost estimates
Guided by the methods used in EQUIPTMOD for modelling
ROI from tobacco control interventions [10], coupled with
data requirements listed in an earlier version of the model
[11], it was deemed necessary to collect estimates for the
following cost-related model inputs: treatment costs [lung
cancer, coronary heart disease (CHD), chronic obstructive
pulmonary disease (COPD) and stroke]; cost attributable
to passive smoking separately for children [asthma, lower
respiratory tract infection (LRTI) and acute otitis media
(AOM)] and adults [asthma, lung cancer and ischaemia
heart disease]; productivity losses [work days lost per
smoker, average hourly wage, employment rates among
smokers]; and costs of implementing interventions. This
studywas restricted to the fourmajor smoking-attributable
diseases as per the EQUIPTMOD requirements. The ratio-
nale for selecting these diseases has been provided by the
model developers elsewhere [10].
Costing perspectives and year
In sourcing the data, a health-care system and a quasi-
societal perspective that included exposure to passive
smoking and productivity gains in the economy due to re-
duced smoking were adopted separately. Spain’s costs were
from the hospital (not the health-care system) perspective,
as no data were available from a health-care perspective.
This clearly underestimated the true health-care costs of
treating smoking-attributable diseases in Spain. We could
not ascertain the size of probable underestimation; nor
were we able to adjust Spanish estimates using data from
the other countries, as the price of health-care goods and
services are very different in Spain compared to the other
countries. All cost data reported in this article were inflated
to 2016/7 prices (in €) using average consumer prices ob-
tained from the World Economic Outlook Database 2015,
although they were entered originally in the EQUIPTMOD
as 2015/6 prices. To aid the comparative quantitative
analysis, the mean unit and annual costs were converted
to 2016/7 euros (€) using country-specific or country-
group-specific inflation on average consumer prices [15].
The annual costs and mean unit values were adjusted by
the interannual inflation rate from the price year to
2017. If required, the unit and annual costs from 2017
were multiplied by the European Central Bank’s 2017 ex-
change rates. For papers not reporting the year in which
the costs were calculated, the publication year was used.
Population
The costs included in the model were derived for the adult
population older than 15 years until they reach a life ex-
pectancy of 100 years in the model. Only passive smoking
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costs were considered for a child population younger than
age 16 years.
Search strategy and inclusion criteria
Country-specific modellers completed focused searches on
respective administrative portals or identified published
sources in each country. The technical document on the
NICE ROI tool [11] that sourced data following a compre-
hensive literature review provided guidance on the type
of administrative data set or published literature that the
countries needed to access first. In addition, countries car-
ried out specific literature reviews and searches in national
and international databases, and a generic Google search
for completeness reasons using the following keywords:
tobacco; smoking; cost*; <input name>. In addition,
country-specific stakeholders that were collaborating with
this project helped with sourcing data. If multiple data
sources were found for a given input value, the specific
country-modelling team evaluated those for their robust-
ness and relevance as per the standardized checklist
(Supporting information, Appendix S1). The country team’s
recommendation was considered final. The selected data
and their sources were then documented in detail together
with reasons for inclusion in a technical annex [16–20].
Consistency checks on included data and internal
validation
A single individual (the principal modeller) incorporated all
country-specific cost estimates into the model. This process
streamlined any inconsistency observed across the coun-
tries. The spreadsheet was then sent back to the respective
country team to double check. Input data were considered
final once both the principal modeller and country teams
agreed on the value and source of the cost estimates.
Obtaining cost of treating smoking-attributable diseases
The annual health-care direct costs stemming from using
health care resources in patients who suffer from
smoking-related diseases were obtained from official re-
ports in Hungary and England [21,22]. In the
Netherlands, official data on costs for lung cancer, CHD,
stroke and COPD were available [23]. Costs of smoking-
related diseases were obtained from the literature in
Germany [24–27] and Spain [28–32]. Further details are
found in country-specific technical annexes [16–20].
Obtaining costs of treating passive smoking-related
diseases
For each country, the population-attributable fraction
(PAF) to second-hand smoke, a model input to attribute
costs to passive smoking, was sourced for three diseases
in adults: asthma (≥ 15 years), lung cancer (≥ 15 years)
and ischaemia heart disease (≥ 15 years) [33] and three
diseases in children: LRTI (≤ 4 years), AOM (≤ 3 years)
and asthma (0–14 years). The total costs of each of these
diseases were sourced from the respective
administrative/published data relevant to those age
groups, thereby allowing the cost of illness attributable to
second-hand smoke exposure to be estimated for each in-
cluded condition.
In the Netherlands, a cost of illness tool [23] was
used to source the cost of respiratory infections and
published literature was used to obtain costs of AOM
[34]. In Spain, asthma total costs and average preva-
lence for the adult Spanish population were obtained
from a published study [35]. For children, costs from
AOM and LRTI were obtained from official diagnosis-
related groups (DRG) data, taking into account only
hospital costs. Asthma total costs were obtained from
the published literature [36]. In Hungary, total costs
due to passive smoking were obtained from an official
report on Economic Burden of Smoking in Hungary
[22]. In Germany, published data [37,38] were used to
derive the total cost of passive smoking in adults,
whereas passive smoking-related costs among children
were sourced from published studies [34,38–42].
Estimating costs of pharmacological interventions
Prices of pharmacological interventions were estimated
from drug cost and the cost of one consultation with a
general practitioner. Intervention specifications such as
medication dosage and duration described elsewhere [43]
were utilized to estimate the total amount of medication
for a course of smoking cessation treatment. Drug prices
for each country were obtained from databases or official
documents [42,44–47]. The final drug cost was estimated
by multiplying the total amount of medication by the
unit price of a medication package. An example of the ap-
plication of this method using varenicline (standard dura-
tion) in England is provided in Supporting information,
Appendix S2. Country-specific reports [16–20] explain
the estimation for all pharmacological interventions. We
assumed that a complete treatment course was given on
a single prescription. This was guided by the need to obtain
the cost estimate that would reflect full implementation of
the intervention. However, it may be typical for general
practitioners to prescribe medications on incremental basis
(additional medication given only if necessary on repeat
prescriptions, to save costs). Therefore, our cost estimates
may be an overestimate of the actual costs in practice.
However, for the purpose of return on investment model-
ling here, we assumed that a full course of treatment was
necessary in order for the interventions to be as effective
as in the original trials [43].
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Estimating costs of behavioural interventions
Costs of behavioural interventions were taken from both
National Health Service (NHS) reports and statistics in
each country and through literature searches. The data
obtained in England [48–51] were also used in Spain, as
no country-specific evidence was available. In Germany,
costs of one-to-one support were obtained based on an As-
sociation of Statutory Health Insurance Physicians report
[52]; the remaining interventions were obtained from
published sources [53,54]. Official databases were available
in Hungary, where the costs of behavioural interventions
were provided [46]. In the Netherlands, cost estimates
of interventions were obtained from the guide for cost
studies [55].
Deriving productivity costs
We derived the costs due to lost productivity according to
the human capital approach using the following inputs:
the percentage of smokers currently employed, the number
of days absent from work in a given year and the average
hourly wage in each country. In England, Germany,
Hungary and Spain data on the number of days lost per
smoker came from the published sources [56–59], whereas
in the Netherlands, reports on health-care figures were
available to derive the number of lost work-days [60]. Aver-
age hourly wage was obtained in all cases through search
and analysis of national databases [61–64]. In the
Netherlands, the hourly wage data were obtained from a
guide for health-care cost studies and research [55]. The
percentage of smokers who were currently employed were
sourced from national statistics for England, Hungary, the
Netherlands and Spain [61,65–67] while in Germany
these data were sourced from a published study [68].
For details of the method used to source or estimate all
cost components included in the ROI model, please refer to
the country-specific technical annexes [16–20]. Data were
presented in five tables: smoking-attributable disease aver-
age annual costs; passive smoking-attributable disease to-
tal annual costs; pharmacological interventions unit
costs; behavioural support intervention unit costs; and
average values of the inputs used to estimate unit produc-
tivity costs.
RESULTS
A summary of the estimates of costs and their sources that
were evaluated to be the ‘best available evidence’ required
to populate the EQUIPTMOD are shown in Tables 1–5.
Some country-level variation in the sources of cost data
was inevitable.
Table 1 shows the average annual costs (per case) for
the treatment of the four smoking-attributable diseases
(LC, CHD, COPD and stroke) for England, Germany,
Hungary, Netherlands and Spain. Treatment costs in the
primary and secondary care settings are included in these
estimates. As these conditions require long-term health-
care (over several years or the life-time), the respective cost
estimates are expressed as ‘annual’. Expressing these costs
as annual estimates was also consistent with the
EQUIPTMOD, as the model uses a yearly cycle. Annual
costs (per case) of treating smoking-attributable lung can-
cer were between €5074 (Hungary) and €52106
(Germany); coronary heart disease between €1521
(Spain) and €3955 (Netherlands); chronic obstructive pul-
monary disease between €1280 (England) and €4199
(Spain); stroke between €1829 (Hungary); and €14880
(Netherlands).
Table 2 shows annual total costs of treating diseases
that could be related to passive smoking for the five coun-
tries. These costs are presented separately for adults and
children. These costs are expressed as the ‘total’ annual
costs (not average, unlike in Table 1), because EQUIPTMOD
applies a fraction (PAF) to the total annual costs to calcu-
late passive smoking-attributable costs [10]. The annual
total costs of treating asthma, lung cancer and CHD in
adults and AOM, LRTI and asthma in children varied
across countries. Total annual costs of treating passive
smoking-attributable asthma in children were between
€1.3 million (Hungary) and €75.7 million (Germany);
and in adults between €28.5 million (Netherlands) and
€332 million (Spain).
Table 1 Annual costs (per case) of treating smoking-attributable diseases (€2016/2017).
Smoking attributable
diseases











Lung cancer 8603.06 [21] 52105.74 [25] 5073.87 [22] 22471.87 [23] 16777.23 [28]
Coronary heart disease 1533.02 [21] 1598.64 [24] 1929.69 [22] 3954.69 [23] 1521.20 [29]
Chronic obstructive
pulmonary disease
1279.97 [21] 3025.61 [26] 2315.57 [22] 1774.65 [69] 4199.08 [31]
Stroke 7233.57 [21] 9923.14 [27] 1829.00 [22] 14879.51 [23] 8472.68 [32]
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Table 3 shows the unit costs for implementing pharma-
cological interventions for the five countries included in the
study. The unit costs are costs per recipient assuming a
complete course of treatment. Costs (per recipient) of
smoking cessation medications were estimated to be: for
standard duration of varenicline between €225 (England)
and €465 (Hungary); for bupropion between €25
(Hungary) and €220 (Germany).
Where an ‘NA’ (not applicable) appears in the table, the
specific intervention did not apply to that particular coun-
try [10]. Differences in the unit costs of pharmacological
interventions across countries show the different level of
prices of medications existing in each of the countries in-
cluded in this study (Table 3). The cost of over-the-counter
mono nicotine replacement therapy (NRT) was assumed to
be zero in England, as the EQUIPTMOD considered the
NHS perspective in costing for England.
Table 4 shows unit costs (costs per recipient) for behav-
ioural interventions for the five countries included in the
study. Costs (per recipient) of providing behavioural sup-
port were also wide-ranging: one-to-one behavioural sup-
port between €34 (Hungary) and €474 (Netherlands);
and group-based behavioural support between €12
(Hungary) and €257 (Germany). The costs (per recipient)
of delivering brief physician advice were: €24 (England);
€9 (Germany); €4 (Hungary); €33 (Netherlands); €27
(Spain).
In Spain, the unit cost data for behavioural interven-
tions were not available and therefore data from England
were assumed to reflect the approximate costs of providing
those interventions there (Table 4). Only country-specific
data regarding the behavioural interventions (printed
self-help materials, one-to-one and group support) were
available for Germany.
Table 5 shows the input values used to estimate produc-
tivity costs for all five countries included in the study. There
was awide variation across countries in terms of the work-
days lost, with England reporting the lowest number of
days lost (2.74 days) and Germany the highest (8.41 days).
As expected, the wage rate also varied throughout the
countries. Average numbers of work-days lost due to
smoking were: 2.74 (England); 8.41 (Germany); 3.58
(Hungary); 6.60 (Netherlands); and 6.00 (Spain).
DISCUSSION
This paper describes a standardized method developed to
source both the economic costs of tobacco and the costs
of implementing interventions for a Europe-wide ROI
model (EQUIPTMOD). The method helped us to improve
consistency in sourcing cost data for a large-scale cross-
country economic model. We hope that the detailed de-
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paper will serve as useful guidance for future similar work
in this area.
One notable benefit of the standardized framework is
that the checklist developed to critically assess the quality
of the cost data has led to improved transparency and
sufficiency in reporting of the data included in the eco-
nomic model. A recently published systematic review [3]
has highlighted how important transparency and suffi-
ciency in reporting are for an economic model to be fully
transferable to other settings. As noted in the systematic
review, it seemed very important to assess the quality of
the cost data in terms of several key attributes: intervention
technologies described; monetary reference used; time
dimension; cost types; costing methods; perspective; and
representativeness. Note that the interventions evaluated
in this study have been described elsewhere [43].
Health-care costs were sourced from different studies
for some countries (i.e. Germany, Spain). One advantage
of the current study has been to identify this methodologi-
cal heterogeneity between the sources of cost data. It is not
Table 4 Unit costs (costs per recipient) of behavioural support interventions (€2016/2017).
Behavioural support
interventions
England Germany Hungary Netherlands Spain
Unit cost source Unit cost source Unit cost source Unit cost source Unit cost source
Specialist behavioural support:
one-to-one
148.85 [79] 303.38 [80] 34.28 [46] 474.15 [55] 163.30 [79]
Specialist behavioural support:
group-based
45.39 [79] 257.10 [53] 11.67 [46] 42.73 [55] 49.77 [79]
Telephone support: proactive 178.64 [77] NA NA 54.48 Expert opinion 121.34 [55] 207.84 [77]
SMS text messaging 20.23 [81] 17.37 [81] NA NA 23.92 [81] 23.23 [81]
Printed self-help materials 16.33 [82] 13.47 [54] 0.68 Expert opinion 1.22 [83] 17.86 [82]
Brief physician advice 24.41 [84] 9.42 [85] 4.12 [44] 33.48 [55] 26.84 [84]
Social marketing 1.44 [84] 1.62 [84] NA NA 1.62 [84] 1.58 [84]
SMS = short messaging service.
Table 5 Input values used to estimate productivity costs (€2016/2017).
England Germany Hungary Netherlands Spain
Productivity costs Units source Units source Units source Units source Units source
Work days lost 2.74 days [56] 8.41 days [57] 3.58 days [58–63] 6.60 days [60] 6.00 days [59]
Wage per hour (unit costs) 13.78€/h [61] 18.35€/h [62] 4.93€/h [63] 35.90€/h [55] 14.97€/h [67]
Table 3 Unit costs (costs per recipient) of pharmacological interventions (€2016/2017).
Pharmacological
interventions
England Germany Hungary Netherlands Spain
Unit cost Source* Unit cost Source* Unit cost Source* Unit cost Source* Unit cost Source*
Rx mono NRT 124.80 [44] NA NA NA NA 229.48 [55,72] 280.52 [73–75]
Rx combo NRT 230.96 [44] NA NA NA NA 482.61 [55,72] 562.49 [73–75]
Varenicline
(standard duration)
225.06 [44] 300.84 [45] 465.25 [46] 332.11 [55,72] 302.80 [73–75]
Varenicline
(extended duration)
417.15 [44] NA NA NA NA 624.47 [55,72] 617.40 [73–75]
Bupropion 93.78 [44] 220.21 [76] 25.16 [46] 179.24 [55,72] 153.55 [73–75]
Nortriptyline 98.59 [44] NA NA NA NA 87.53 [55,72] NA NA
Cytisine 19.69 [21] NA NA NA NA NA NA NA NA
OTC mono NRT 0,00 [77] 326.50 [45] 148.67 [78] NA NA 356.26 [75]
OTC combo NRT n.a. n.a. 573.20 [42] NA NA NA NA NA NA
*Direct or indirect source. Where indirect, the authors estimated the costs using inputs data available from this source. NRT = nicotine replacement therapy;
OTC = over-the-counter; NA = not applicable.
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uncommon to estimate cost-of-illness using different ap-
proaches [86], but it is only when applying a standardized
checklist that one could identify what causes the variation.
The wage rates as well as the intensity of support were the
cost drivers for the behavioural interventions. However, the
most significant variation was observed for the annual av-
erage costs of treating the four smoking-attributable dis-
eases. This variation was driven mainly by the differences
in the prices of health-care goods and services across the
countries. While it is normal for countries to vary in terms
of health-care costs, showing this variation explicitly helps
policymakers to understandmore clearly the ROI estimates
that would be produced by using such cost inputs.
Despite taking the NHS perspective, disease costs used
in the model for Spain had to rely upon hospitalization
costs only. Therefore, the treatment costs predicted by the
EQUIPTMOD for Spain are underestimates. This highlights
the lack of data related to smoking-attributable health-care
costs in some countries in Europe, particularly from an
NHS perspective. Future cost-of-illness studies in those
countries should focus upon collecting data from the NHS
and wider perspectives.
Some countries lacked specific cost data (e.g. on behav-
ioural support interventions in Spain) required by the ROI
model. Upon careful evaluation by the country teams, the
available English data were used in those cases, assuming
that they would be representative of the population in the
country in question. This remains an important limitation
of our standardized methods and can only be validated
once such data become available in those countries. When
countries begin to consider collection of such data in the
future, it would be helpful to evaluate different methodo-
logical options, e.g. micro-costing in which intervention
costs are built up based on cost ingredients or observa-
tional costings where actual resource use is tracked along-
side a clinical trial. In Spain, for example, there have been
some initiatives to develop costing guidelines for different
diseases [87,88] and our findings may offer some useful
insights to those initiatives as they advance.
CONCLUSION
The costs of treating smoking-attributable diseases as well
as the costs of implementing smoking cessation interven-
tions vary substantially across the five study countries.
Estimates for the costs of these diseases and interventions
can contribute to return on investment estimates in
support of national or regional policy decisions.
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